SCOPUS 정보 검색 플랫폼

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 370-

Authors' response

(2) Huang, Shiew Mei a Lesko, Lawrence J a

a CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; MIDAZOLAM; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; COMPUTER MODEL; DRUG ABSORPTION; DRUG DESIGN; DRUG HALF LIFE; DRUG INHIBITION; FOOD AND DRUG ADMINISTRATION; LETTER; MEDICAL LITERATURE;

EID: 61449101599 PISSN: 00912700 EISSN: 15524604 Source Type: Journal
DOI: 10.1177/0091270008330989 Document Type: Letter

Times cited : (9)

References (6)

1
- 84868896989
- http://www.fda.gov/cder/guidance/index.htm#clinical%20pharmacologyorhttp: //www.fda.gov/Cder/drug/drugInteractions/default.htm
- US Food and Drug Administration. Draft guidance: guidance for industry drug interaction studies-study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/cder/Guidance/6695dft.htm ; for updated guidance, see http://www.fda.gov/cder/guidance/index. htm#clinical%20pharmacologyorhttp://www.fda.gov/Cder/drug/drugInteractions/ default.htm.
- Draft Guidance: Guidance for Industry Drug Interaction Studies-study Design, Data Analysis, and Implications for Dosing and Labeling
- Food, U.S.¹ Administration, D.²

2
- 33846577441
- Drug-drug interactions: Study design, data analysis and implications for dosing recommendations
- Huang S. -M, Temple R., Throckmorton DC, Lesko L. Drug-drug interactions: study design, data analysis and implications for dosing recommendations. Clin Pharmacol Ther. 2007 ; 81 (2). 298-304.
- (2007) Clin Pharmacol Ther , vol.81 , Issue.2 , pp. 298-304
- Huang, S.¹ Temple, R.² Throckmorton, D.C.³ Lesko, L.⁴

3
- 61449262857
- The need of multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study
- Oo C., Chen YC The need of multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol. 2009 ; 49: 368-369.
- (2009) J Clin Pharmacol , vol.49 , pp. 368-369
- Oo, C.¹ Chen, Y.C.²

4
- 61449144327
- An open label study to determine how different durations of ketoconazole (ket) dosing inhibit cytochrome P450 3A4 (CYP3A4) as assessed by midazolam (MDZ) pharmacokinetics (PK)
- Friedman E., Maes A., Xu Y., et al. An open label study to determine how different durations of ketoconazole (ket) dosing inhibit cytochrome P450 3A4 (CYP3A4) as assessed by midazolam (MDZ) pharmacokinetics (PK). Clin Pharmacol Ther. 2008 ; 81 (3). PIII-58.
- (2008) Clin Pharmacol Ther. , vol.81 , Issue.3 , pp. 58
- Friedman, E.¹ Maes, A.² Xu, Y.³

5
- 33745281869
- Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
- Chien JY, Lucksiri A., Ernest CS II, Gorski JC, Wrighton SA, Hall SD Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos. 2006 ; 34 (7). 1208-1219.
- (2006) Drug Metab Dispos. , vol.34 , Issue.7 , pp. 1208-1219
- Chien, J.Y.¹ Lucksiri, A.² Ernest Cs, I.I.³ Gorski, J.C.⁴ Wrighton, S.A.⁵ Hall, S.D.⁶

6
- 61449149436
- Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: A simulation study
- Zhao P., Ragueneau-Majlessi I., Zhang L., et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol. 2009 ; 49: 351-359.
- (2009) J Clin Pharmacol , vol.49 , pp. 351-359
- Zhao, P.¹ Ragueneau-Majlessi, I.² Zhang, L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.